Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 11.37
(-0.26%)
CNY 11.37
(-0.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.89 Billion CNY | -19.75% |
| 2022 | 3.6 Billion CNY | -9.35% |
| 2021 | 3.98 Billion CNY | 7.47% |
| 2020 | 3.7 Billion CNY | 14.92% |
| 2019 | 3.22 Billion CNY | 20.02% |
| 2018 | 2.68 Billion CNY | 36.31% |
| 2017 | 1.96 Billion CNY | 32.32% |
| 2016 | 1.48 Billion CNY | 39.77% |
| 2015 | 1.06 Billion CNY | 13.94% |
| 2014 | 934.84 Million CNY | 19.94% |
| 2013 | 779.42 Million CNY | 28.59% |
| 2012 | 606.15 Million CNY | 16.28% |
| 2011 | 521.3 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 612.33 Million CNY | -21.56% |
| 2024 Q2 | 654.72 Million CNY | 6.92% |
| 2024 Q3 | 668.7 Million CNY | 2.13% |
| 2023 Q4 | 780.68 Million CNY | 6.31% |
| 2023 Q1 | 676.4 Million CNY | -24.01% |
| 2023 Q2 | 704.32 Million CNY | 4.13% |
| 2023 Q3 | 734.35 Million CNY | 4.26% |
| 2023 FY | 2.89 Billion CNY | -19.75% |
| 2022 Q2 | 857.08 Million CNY | -7.31% |
| 2022 Q1 | 924.72 Million CNY | -4.8% |
| 2022 FY | 3.6 Billion CNY | -9.35% |
| 2022 Q4 | 890.12 Million CNY | -4.95% |
| 2022 Q3 | 936.48 Million CNY | 9.26% |
| 2021 Q1 | 1.06 Billion CNY | -8.92% |
| 2021 Q4 | 971.36 Million CNY | -7.39% |
| 2021 FY | 3.98 Billion CNY | 7.47% |
| 2021 Q3 | 1.04 Billion CNY | 17.74% |
| 2021 Q2 | 890.83 Million CNY | -16.71% |
| 2020 Q1 | 518.83 Million CNY | -40.72% |
| 2020 FY | 3.7 Billion CNY | 14.92% |
| 2020 Q4 | 1.17 Billion CNY | 9.03% |
| 2020 Q3 | 1.07 Billion CNY | 15.36% |
| 2020 Q2 | 933.63 Million CNY | 79.95% |
| 2019 Q4 | 875.18 Million CNY | 5.37% |
| 2019 Q3 | 830.54 Million CNY | 4.49% |
| 2019 Q2 | 794.82 Million CNY | 10.02% |
| 2019 FY | 3.22 Billion CNY | 20.02% |
| 2019 Q1 | 722.4 Million CNY | -1.12% |
| 2018 Q4 | 730.6 Million CNY | 3.15% |
| 2018 Q2 | 727.5 Million CNY | 40.19% |
| 2018 Q1 | 518.92 Million CNY | -15.42% |
| 2018 FY | 2.68 Billion CNY | 36.31% |
| 2018 Q3 | 708.26 Million CNY | -2.64% |
| 2017 Q1 | 363.14 Million CNY | -17.81% |
| 2017 Q2 | 480.05 Million CNY | 32.19% |
| 2017 FY | 1.96 Billion CNY | 32.32% |
| 2017 Q3 | 513.24 Million CNY | 6.91% |
| 2017 Q4 | 613.54 Million CNY | 19.54% |
| 2016 Q3 | 377.95 Million CNY | -2.46% |
| 2016 FY | 1.48 Billion CNY | 39.77% |
| 2016 Q4 | 441.81 Million CNY | 16.9% |
| 2016 Q2 | 387.48 Million CNY | 37.63% |
| 2016 Q1 | 281.53 Million CNY | -11.33% |
| 2015 Q2 | 306.21 Million CNY | 47.08% |
| 2015 Q1 | 208.2 Million CNY | -24.53% |
| 2015 FY | 1.06 Billion CNY | 13.94% |
| 2015 Q4 | 317.51 Million CNY | 36.14% |
| 2015 Q3 | 233.22 Million CNY | -23.84% |
| 2014 FY | 934.84 Million CNY | 19.94% |
| 2014 Q4 | 275.88 Million CNY | 33.46% |
| 2014 Q1 | 183.65 Million CNY | 0.0% |
| 2014 Q3 | 206.72 Million CNY | -23.03% |
| 2014 Q2 | 268.57 Million CNY | 46.24% |
| 2013 FY | 779.42 Million CNY | 28.59% |
| 2012 FY | 606.15 Million CNY | 16.28% |
| 2011 FY | 521.3 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 78.403% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 60.783% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -112.406% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | -66.268% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | -53.551% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | -4.733% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -162.19% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 33.425% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -178.752% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -72.947% |